EC announces EU pharma reform that cuts market exclusivity

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled, indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity.

Described as the largest reform in over 20 years, the proposed revision touches on multiple topics ranging from unequal access to innovative medicines across the EU to new environmental protections. Notably, this includes the reduction of regulatory data protection from eight years to six— a decision which will likely prove controversial.

Read more
As Eylea sales fall again, Regeneron looks forward to approval of its longer-lasting follow-up.

For Regeneron, seven weeks can’t come soon enough. That’s when its longer-acting version of macular degeneration drug Eylea is up for a potential FDA approval.

Until then however, Regeneron and partner Bayer are taking a hit as customers are turning to Roche’s Vabysmo, which has a longer-acting formula, allowing age-related macular degeneration (AMD) and diabetic macular edema (DME) patients to take three annual shots to the eyeball instead of six.

Read more
Enoxaparin – New Reliable Supply from Trusted Source

The Hepalink Group is a global leader in naturally extracted active pharmaceutical ingredients (API) and finished drugs that draw from an extremely diverse and robust network. The Hepalink supply chain draws raw materials from North America, Europe, and Asia. The Hepalink Group owns and operates North America’s largest producer of Heparin API, Scientific Protein Laboratories (SPL). This API business was created by Oscar Mayer back in the 1970s and has continually supplied Heparin API to the global market since their formation. SPL continues to be a global leader in naturally extracted API production.

Read more
Sanofi releases AVAXIM Junior in the UK

Therapy provides immunisation against infection caused by hepatitis A in children aged 12 months to 15 years.

Sanofi has revealed that it is launching AVAXIM Junior across the UK. The treatment is an inactive hepatitis A vaccine for use in children aged 12 months to 15 years and has been developed to prevent infection caused by the hepatitis A virus.

Read more

Need pharmaceutical supplies?

We are able to source and supply pharmaceuticals globally and currently have customers located
as far afield as the Middle East, Africa, Asia and Europe.

+44 (0) 33 3123 4558